Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 210-248-3 | CAS number: 611-06-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
In an acute oral toxicity study 10 male or female Wistar rats were treated via gavage with 20 ml/kg bw of test substance.
The LD 50 was 379 mg/kg bw or 385 mg/kg bw , respectively(Löser E, Bayer AG, 1982).
In an acute dermal toxicity study in male and female Wistar rats the LD50 was 921 mg/kg bw in female animals. Male rats did not react more sensitive. (Hofmann/ Jung, Hoechst AG, 1988)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: No OECD guideline or GLP defined.
- Principles of method if other than guideline:
- Method: other: acute toxicity oral: male rats
- GLP compliance:
- not specified
- Test type:
- other: acute oral toxicity study
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Route of administration:
- oral: gavage
- Vehicle:
- other: Lutrol
- Doses:
- 20 ml/kg bw
- No. of animals per sex per dose:
- 10
- Control animals:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 379 mg/kg bw
- Executive summary:
In an acute oral toxicity study 10 male Wistar rats were treated via gavage with 20 ml/kg bw of test substance.
Signs of intoxication were: narcosis, face-down position and lateral position, scrubby fur, diminuated general condition.
The LD 50 was 379 mg/kg bw.
Reference
SO-Freetext: Hoechst AG Frankfurt 80
Hoechst AG Frankfurt/Main
RM-Freetext:
maennlich
RM-Freetext:
Verabreichung per Magensonde, Symptome: Narkose, struppiges
Fell, Bauch- und Seitenlage, Herabsetzung des Allgemeinbe-
findens, erhoehte Diurese, keine substanzbedingten makros-
kopischen Veraenderungen.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 379 mg/kg bw
- Quality of whole database:
- The studies are performed similar to the respective guidelines
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- GLP compliance:
- yes
- Test type:
- other: acute dermal toxicity study
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Type of coverage:
- occlusive
- Vehicle:
- other: 0.9 % saline
- Duration of exposure:
- 24 h
- Doses:
- male rats: 2000 mg/kg bw.; female rats: 500, 800, 1000, 1250, 2000 mg/kg bw.
- No. of animals per sex per dose:
- 5
- Control animals:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 921 mg/kg bw
- Executive summary:
In an acute dermal toxicity study in male and female Wistar rats the LD50 was 921 mg/kg bw in female animals. Male rats did not react more sensitive. Doses up to 2000 mg/kg bw. were applied occlusively to the back skin of the rats. Mortality occurred mostly in the night. Symptoms observed were, unspecific symptoms and disturbed course of movement.. In one animal narrowed palpebral fissures were observed. One female animal of the 1250 mg/kg group showed pallidness of skin, drowsiness, diminuated startle reflexes and diminuated breathing frequency.
5 days after treatment all surviving animals were free of symptoms.
No bodyweight abnormalities were observed.
Died animals showed staining at liver, lung and spleen. In the killed animals no abnormalities were observed.
Regarding the LD50 of 921 mg/kg bw the test substance was found to be slightly toxic according to directive 83/467/EWG and therefore classified as R21.
Reference
Mortality:
male rats | female rats | |||
Dose (mg/kg bw) | absolute | relative (%) | absolute | relative (%) |
500 | - | - | 0/5 | 0 |
800 | - | - | 2/5 | 40 |
1000 | - | - | 2/5 | 40 |
1250 | - | - | 5/5 | 100 |
2000 | 4/5 | 80 | 5/5 | 100 |
LD50 (mg/kg bw.) 921
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 921 mg/kg bw
- Quality of whole database:
- This is the only available study which was performed according to the respective guideline and GLP and evaluated with Klimisch Score 1
Additional information
ORAL APPLICATION
In an acute oral toxicity study 10 male Wistar rats were treated via gavage with 20 ml/kg bw of test substance. Signs of intoxication were: narcosis, face-down position and lateral position, scrubby fur, diminuated general condition. The LD 50 was 379 mg/kg bw (Löser E, Bayer AG, 1982). In an acute oral toxicity study 10 female Wistar rats were treated via gavage with 20 ml/kg bw of test substance. Signs of intoxication were: narcosis, face-down position and lateral position, scrubby fur, hightened diuresis, diminuated general condition.The LD 50 was 385 mg/kg bw (Löser E. Bayer AG, 1982).
Furthermore, in an acute oral gavage toxicity study in cats the animals received 10 and 50 mg/kg bw of test substance in a single dose.
The met-hemoglobin concentration and the number of HEINZ-bodies were not increased after 3, 7, and 24 hours.
Up to 8 hours after application a loss of appetite was observed. No other symptoms were noticed.
Based on these results and taking into account that cats are highly susceptible for blood toxicity (e.g. methemoglobin formation) it can be concluded that 1,3 -dichloronitrobenzene does not induce methemoglobin formatation
DERMAL APPLICATION
In an acute dermal toxicity study in male and female Wistar rats the LD50 was 921 mg/kg bw in female animals. Male rats did not react more sensitive. Doses up to 2000 mg/kg bw. were applied occlusively to the back skin of the rats. Mortality occurred mostly in the night. Symptoms observed were, unspecific symptoms and disturbed course of movement.. In one animal narrowed palpebral fissures were observed. One female animal of the 1250 mg/kg group showed pallidness of skin, drowsiness, diminuated startle reflexes and diminuated breathing frequency. 5 days after treatment all surviving animals were free of symptoms. No bodyweight abnormalities were observed. Died animals showed staining at liver, lung and spleen. In the killed animals no abnormalities were observed. Regarding the LD50 of 921 mg/kg bw the test substance was found to be slightly toxic according to directive 83/467/EWG and therefore classified as R21 (Hofmann/ Jung, Hoechst AG, 1988).
Justification for selection of acute toxicity – oral endpoint
There are 2 studies available which were performed in equal quality : one with male rats leading to LD50 of 379 mg/kg bw and one with female rats leading to LD50 of 385 mg/kg bw
Justification for selection of acute toxicity – dermal endpoint
This is the only available study which was performed according to the respective guideline and GLP and evaluated weoth Klimisch Score 1
Justification for classification or non-classification
1,3-dichloro-4-nitrobenzene should be classified R21/22 according to 67/548/EWG, as "acute tox oral cat 4" and "acute tox dermal cat 3" according to 1272/2008 (GHS).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
